Lentiviral vectors offer several advantages over other types of gene delivery systems including high transduction efficiency, stable transgene expression, and the ability to transduce non-dividing cells. They have emerged as a promising alternative to gammaretroviral and adenoviral vectors for applications in gene therapy, cell engineering, and other life science research areas.
The global lentiviral vectors market is estimated to be valued at US$ 336.39 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031.
Key Takeaways
Key players: Key players operating in the lentiviral vectors market include Tata Communications Ltd., Amazon CloudFront– Amazon.com Inc., Cachefly, CDNetworks Co., Ltd., CDNify Ltd., CDNsun, CDNvideo, CloudFlare, Inc., EdgeCast Networks, Fastly, Proinity LLC, Limelight Networks Inc., Skypark CDN, and Level 3 Communication Inc. Major players are focused on expanding their product portfolios and global footprint via partnerships and acquisitions.
Growing demand: Lentiviral Vectors Market Increasing prevalence of genetic disorders, cancer, and infectious diseases along with rising funding for gene therapy research is expected to drive the demand for lentiviral vectors over the forecast period. They offer promising treatment alternatives and are being extensively researched for development of new gene therapies.
Global expansion: Leading companies are focused on expanding their manufacturing facilities and establishing production units in different geographies to cater to the growing global demand. For instance, in 2020, Pharming Group N.V. set up a new facility in the US to enhance manufacturing of lentiviral vectors. Several firms are also investing in developing lentiviral vector platforms optimized for various therapy areas.
Market key trends
CRISPR technology integration: Lentiviral vector platforms are being combined with CRISPR/Cas9 genome editing tools to develop more targeted and efficient gene therapies. This trend allows delivery of CRISPR components like Cas9 and sgRNAs using vectors for in vivo therapeutic applications.
Focus on scalable production: Major players are investing in automated, scalable manufacturing techniques to increase lentiviral vector yields and support large-scale clinical trials and commercialization. This is important for enhancing process consistency and reducing costs.
Porter's Analysis
Threat of new entrants: The biotechnology and pharmaceutical industry requires high capital investments limiting threat of new entrants. However, the lentiviral vectors market has relatively lower entry barriers.
Bargaining power of buyers: Due to several key players in the market, buyers have high bargaining power to negotiate on pricing. However, requirement of technical expertise limits bargaining power.
Bargaining power of suppliers: Suppliers of raw materials have moderate bargaining power due to availability of substitute materials suppliers.
Threat of new substitutes: New cell and gene therapy modalities pose threat of substitution. However, lentiviral vectors are established with no direct substitute.
Competitive rivalry: The market is dominated by few players intensifying competition. Players differentiate through product portfolio expansion.
Geographical Regions
North America region dominated the global lentiviral vectors market in terms of value in 2024 due to extensive research in gene and cell therapy along with presence of major market players. The United States contributed significantly to North America due to well-established biopharmaceutical industry and healthcare infrastructure supporting clinical research.
The Asia Pacific region is expected to witness the fastest growth during the forecast period from 2024 to 2031. This is attributed to factors such as increasing healthcare investments, expanding biopharmaceutical industry, and growing research funding for developing novel gene and cell therapies in countries including China and India. Rising disease burden and growing awareness create demand for advanced treatment such as lentiviral vectors based gene therapy in Asia Pacific.
Get more insights on This Topic- Lentiviral Vectors Market
Comments
0 comment